Table 2.

Effects of CD200Fc treatment on the infiltration of CD11b⁺ and other inflammatory cell types into the spinal cord-flow cytometric analysis

	15 d after immunization				30 d after immunization
	Spinal cord		Spleen		Spinal cord		Spleen
	Control-treated	CD200Fc-treated	Control-treated	CD200Fc-treated	Control-treated	CD200Fc-treated	Control-treated	CD200Fc-treated
%CD11b+CD45+	2.48 ± 0.39	1.16 ± 0.19**	11.76 ± 1.86	16.56 ± 1.88*	5.26 ± 0.59	2.19 ± 0.56**	11.85 ± 2.76	9.10 ± 1.75
%CD11b +CD45−	5.59 ± 0.49	3.75 ± 0.56*			4.67 ± 0.45	3.92 ± 0.40#
%CD4+	3.00 ± 0.52	2.15 ± 0.40#	26.51 ± 3.54	23.28 ± 3.38	1.82 ± 0.33	1.52 ± 0.29	23.13 ± 3.72	23.37 ± 3.32
%CD8+	2.63 ± 0.48	1.95 ± 0.32#	14.16 ± 2.17	12.61 ± 2.18	1.42 ± 0.36	1.16 ± 0.35	11.25 ± 3.35	11.55 ± 3.65
%CD19+	1.82 ± 0.47	1.52 ± 0.50	48.56 ± 6.13	46.54 ± 4.88	1.20 ± 0.32	1.06 ± 0.21	41.52 ± 5.55	42.70 ± 7.38
%Gr-1+	1.41 ± 0.31	1.13 ± 0.30			2.11 ± 0.56	1.16 ± 0.45#
Total number of cells/spinal cordor spleen (×106)	1.17 ± 0.23	0.66 ± 0.15*	94.05 ± 9.86	127.75 ± 13.71*	0.88 ± 0.14	0.52 ± 0.12*	98.85 ± 12.03	96.27 ± 11.30

Four to six mice per group with average clinical EAE were examined. Mice were treated with CD200Fc versus control IgG2a from day 10. At day 15 or 30, the treated animals were killed, and flow cytometric analysis was performed for spleenocytes or cells isolated from spinal cord homogenates. All molecule expression was analyzed with gating on live cells. Data are presented as means ± SD. Statistical comparison was made using two-tailed t test.

^#p < 0.05;

*p < 0.01;

**p < 0.001 versus control-treated groups.